Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway

Journal of Controlled Release

Volumn 156, Issue 3, 2011, Pages 381-389

  Seki, Takahiro ^a   Carroll, Fionnadh ^a   Illingworth, Sam ^b   Green, Nicky ^a,b   Cawood, Ryan ^a   Bachtarzi, Houria ^a   Šubr, Vladimir ^c   Fisher, Kerry D ^a,b   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PSIOXUS THERAPEUTICS LTD   (United Kingdom)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Adenovirus; Drug delivery; EPR effect; Rho A Rho kinase inhibitor; Tumour necrosis factor ; Vascular permeability

Indexed keywords

ADENOVIRUS; CHEMOTHERAPEUTIC DRUGS; CYTOKINES; EPR-EFFECT; EVANS BLUE; IN-VITRO; INTRAVENOUS ADMINISTRATION; KINASE INHIBITORS; NECROSIS FACTORS; RHO-KINASE INHIBITORS; THERAPEUTIC AGENTS; TUMOUR CELLS; TUMOUR TISSUE; VASCULAR PERMEABILITY; VIRAL INFECTIONS; VIRAL PARTICLES; VIROTHERAPY;

DRUG DELIVERY; ENDOTHELIAL CELLS; ENZYMES; GLYCOPROTEINS; MACROPHAGES; VIRUSES;

TUMORS;

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CAPILLARY PERMEABILITY; CELL LINE; ENDOTHELIUM, VASCULAR; HUMANS; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VIRION;

EID: 82755197640     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.08.022     Document Type: Article

References (36)

1. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
2. H. Maeda, L.W. Seymour, and Y. Miyamoto Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjug. Chem. 3 1992 351 362
3. S.E. Goldblum, X. Ding, and J. Campbell-Washington TNF-alpha induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction Am. J. Physiol. 264 1993 C894 C905
4. T.L. Hagen, and A.M. Eggermont Tumor vascular therapy with TNF: critical review on animal models Methods Mol. Med. 98 2004 227 246
5. J.H. Schiller, B.E. Storer, P.L. Witt, D. Alberti, M.B. Tombes, R. Arzoomanian, R.A. Proctor, D. McCarthy, R.R. Brown, and S.D. Voss Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly Cancer Res. 51 1991 1651 1658
6. A.M. Eggermont, H. Schraffordt Koops, J.M. Klausner, B.B. Kroon, P.M. Schlag, D. Lienard, A.N. van Geel, H.J. Hoekstra, I. Meller, O.E. Nieweg, C. Kettelhack, G. Ben-Ari, J.C. Pector, and F.J. Lejeune Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann. Surg. 224 1996 756 764 discussion 764-755
7. F.J. Lejeune, D. Lienard, M. Matter, and C. Ruegg Efficiency of recombinant human TNF in human cancer therapy Cancer Immun. 6 2006 6
8. D.J. Grunhagen, F. Brunstein, W.J. Graveland, A.N. van Geel, J.H. de Wilt, and A.M. Eggermont One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases Ann. Surg. 240 2004 939 947 discussion 947-938
9. R.C. Carlisle, Y. Di, A.M. Cerny, A.F. Sonnen, R.B. Sim, N.K. Green, V. Subr, K. Ulbrich, R.J. Gilbert, K.D. Fisher, R.W. Finberg, and L.W. Seymour Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1 Blood 113 2009 1909 1918
10. V. Subr, L. Kostka, T. Selby-Milic, K. Fisher, K. Ulbrich, L.W. Seymour, and R.C. Carlisle Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components J. Control. Release 135 2009 152 158
11. N.K. Green, C.W. Herbert, S.J. Hale, A.B. Hale, V. Mautner, R. Harkins, T. Hermiston, K. Ulbrich, K.D. Fisher, and L.W. Seymour Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus Gene Ther. 11 2004 1256 1263 (Pubitemid 39173432)
12. M. Koss, G.R. Pfeiffer II, Y. Wang, S.T. Thomas, M. Yerukhimovich, W.A. Gaarde, C.M. Doerschuk, and Q. Wang Ezrin/radixin/moesin proteins are phosphorylated by TNF-alpha and modulate permeability increases in human pulmonary microvascular endothelial cells J. Immunol. 176 2006 1218 1227 (Pubitemid 43099726)
13. M. Amano, M. Ito, K. Kimura, Y. Fukata, K. Chihara, T. Nakano, Y. Matsuura, and K. Kaibuchi Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) J. Biol. Chem. 271 1996 20246 20249 (Pubitemid 26281788)
14. K. Kimura, M. Ito, M. Amano, K. Chihara, Y. Fukata, M. Nakafuku, B. Yamamori, J. Feng, T. Nakano, K. Okawa, A. Iwamatsu, and K. Kaibuchi Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) Science 273 1996 245 248 (Pubitemid 26285892)
15. K.D. Fisher, Y. Stallwood, N.K. Green, K. Ulbrich, V. Mautner, and L.W. Seymour Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies Gene Ther. 8 2001 341 348 (Pubitemid 32241933)
16. N.K. Green, and L.W. Seymour Adenoviral vectors: systemic delivery and tumor targeting Cancer Gene Ther. 9 2002 1036 1042 (Pubitemid 35462565)
17. J.H. de Wilt, T.L. ten Hagen, G. de Boeck, S.T. van Tiel, E.A. de Bruijn, and A.M. Eggermont Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br. J. Cancer 82 2000 1000 1003 (Pubitemid 30128849)
18. T. Seki, J. Fang, and H. Maeda Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application Cancer Sci. 100 2009 2426 2430
19. R. Puro, and R.J. Schneider Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA J. Virol. 81 2007 7351 7362 (Pubitemid 47047824)
20. K.A. Parato, D. Senger, P.A. Forsyth, and J.C. Bell Recent progress in the battle between oncolytic viruses and tumours Nat. Rev. Cancer 5 2005 965 976 (Pubitemid 41766784)
21. E. Ferrero, M.R. Zocchi, E. Magni, M.C. Panzeri, F. Curnis, C. Rugarli, M.E. Ferrero, and A. Corti Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability Am. J. Physiol. Cell Physiol. 281 2001 C1173 C1179
22. J.L. Abbruzzese, B. Levin, J.A. Ajani, J.S. Faintuch, S. Saks, Y.Z. Patt, C. Edwards, K. Ende, and J.U. Gutterman Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Res. 49 1989 4057 4061 (Pubitemid 19197445)
23. F.R. Balkwill, B.G. Ward, E. Moodie, and W. Fiers Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer Cancer Res. 47 1987 4755 4758 (Pubitemid 17143014)
24. T.L. ten Hagen, A.L. Seynhaeve, S.T. van Tiel, D.J. Ruiter, and A.M. Eggermont Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats Int. J. Cancer 97 2002 115 120
25. A. Yilmaz, G. Bieler, O. Spertini, F.J. Lejeune, and C. Ruegg Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology Int. J. Cancer 77 1998 592 599 (Pubitemid 28340909)
26. A.M. Eggermont, H. Schraffordt Koops, D. Lienard, B.B. Kroon, A.N. van Geel, H.J. Hoekstra, and F.J. Lejeune Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J. Clin. Oncol. 14 1996 2653 2665 (Pubitemid 26329649)
27. D. Lienard, P. Ewalenko, J.J. Delmotte, N. Renard, and F.J. Lejeune High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J. Clin. Oncol. 10 1992 52 60
28. C. Ruegg, A. Yilmaz, G. Bieler, J. Bamat, P. Chaubert, and F.J. Lejeune Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat. Med. 4 1998 408 414 (Pubitemid 28212755)
29. T.L. Ten Hagen, A.H. Van Der Veen, P.T. Nooijen, S.T. Van Tiel, A.L. Seynhaeve, and A.M. Eggermont Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats Int. J. Cancer 87 2000 829 837 (Pubitemid 30660563)
30. D. Oupicky, M. Ogris, K.A. Howard, P.R. Dash, K. Ulbrich, and L.W. Seymour Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation Mol. Ther. 5 2002 463 472 (Pubitemid 34308672)
31. K.D. Fisher, N.K. Green, A. Hale, V. Subr, K. Ulbrich, and L.W. Seymour Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy J. Drug Target. 15 2007 546 551 (Pubitemid 47209055)
32. J. Morrison, S.S. Briggs, N. Green, K. Fisher, V. Subr, K. Ulbrich, S. Kehoe, and L.W. Seymour Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor Mol. Ther. 16 2008 244 251 (Pubitemid 351168032)
33. L. Crippa, A. Gasparri, A. Sacchi, E. Ferrero, F. Curnis, and A. Corti Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha Cancer Res. 68 2008 1154 1161 (Pubitemid 351272234)
34. E. Kakiashvili, P. Speight, F. Waheed, R. Seth, M. Lodyga, S. Tanimura, M. Kohno, O.D. Rotstein, A. Kapus, and K. Szaszi GEF-H1 mediates tumor necrosis factor-alpha-induced Rho activation and myosin phosphorylation: role in the regulation of tubular paracellular permeability J. Biol. Chem. 284 2009 11454 11466
35. P.Y. Mong, C. Petrulio, H.L. Kaufman, and Q. Wang Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells J. Immunol. 180 2008 550 558
36. G.P. van Nieuw Amerongen, M.A. Vermeer, P. Negre-Aminou, J. Lankelma, J.J. Emeis, and V.W. van Hinsbergh Simvastatin improves disturbed endothelial barrier function Circulation 102 2000 2803 2809